For example, a retrospective study including metastatic NSCLC patients treated with the anti-PD-1 antibody nivolumab found that low tumor GDF15 expression was associated with OS, PFS, and ORR, suggesting that GDF15 may identify subsets of patients less likely to benefit from immunotherapy [156]. Here, GDF15 is linked to neoplasm.